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Abstract. The Biopharmaceutics Classiﬁcation System (BCS) is based on the mechanistic assumptions
that the rate and extent of oral drug absorption are governed by drug solubility, intestinal permeability,
and dissolution rate from the dosage form administered. One of the goals of BCS is to identify classes of
drugs for which bioequivalence may be established based solely on the in vitro dissolution data, i.e.,
which would be eligible for biowaiver. On the basis of BCS, currently, the biowaiver concept is adopted
and recommended for immediate release of drug products containing highly soluble and highly
permeable compounds (BCS class 1 drugs). Dissolution testing properties are proposed to be more
stringent: very rapid dissolution is demanded when generic drug application is submitted with the
exemption of in vivo bioequivalence study. In the present paper, Gastrointestinal Simulation Technology
has been applied in order to evaluate the potential for different in vitro drug dissolution kinetics to
inﬂuence dosage forms in vivo behavior and the relevance of “very rapid dissolution” criteria to be met
(i.e., more than 85% of dose dissolved in 15 min).
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INTRODUCTION
With the introduction of Biopharmaceutics Classiﬁcation
System (BCS) and the biowaiver concept, the essential
requirement in generic drug approval process, the demonstra-
tion of similarity of rate and extent of drug absorption between
the investigated and the reference, innovator product, has been
shifted from the in vivo human bioequivalence study to the
possibility to waive it based on the surrogate in vitro data (1).
The BCS has been introduced as a scientiﬁc framework for
classifying drug substances according to their aqueous solubility
and intestinal permeability (2). It is based on the mechanistic
assumptions that the rate and extent of oral drug absorption are
governed by drug solubility, intestinal permeability, and
dissolution rate from the dosage form administered (3). One
of the goals of BCS is to identify classes of drugs for which
bioequivalence may be established based solely on the in vitro
dissolution data, i.e., which would be eligible for biowaiver. At
present, the biowaiver concept is adopted and recommended
for the immediate release of drug products containing highly
soluble and highly permeable compounds (BCS class 1 drugs)
(4,5). Biowaiver extensions have also been discussed for BCS
class 3 drugs (6) as well as for class 2 drugs under the
presumption that they dissolve completely during the gastroin-
testinal passage (7). Not only generic drug manufacturers may
beneﬁt from biowaiver applications. BCS principles are in-
creasingly used in the development of New Chemical Entities
where BCS-based waiver of in vivo studies can result in
signiﬁcant savings, particularly during the late stages of clinical
testing when formulation adjustments are performed (8).
The general recognition of the low risk associated with the
biowaiver decision for class 1 drugs initiated further discus-
sions regarding the appropriate regulatory requirements and
recommendations. While the ICHQ6Guideline (9) recognizes
that for highly soluble or highly permeable drug substances,
the requirement for dissolution testing, under certain circum-
stances, might be replaced by disintegration testing; the
regulatory authorities in Europe tend to ask for more stringent
dissolution speciﬁcations in order to justify the biowaiver
application (10). In the present paper, Gastrointestinal Simu-
lation Technology (GST) has been applied in order to evaluate
the potential for different in vitro drug-dissolution kinetics to
inﬂuence dosage forms in vivo behavior and the relevance of
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“very rapid dissolution” criteria (i.e., more than 85% of dose
dissolved in 15 min). Gastrointestinal simulation studies were
performed for a range of BCS class 1 model drugs (including
ketoprofen as border line class I/II substance) based on the
virtual set of in vitro proﬁles representing the lower boundary
of “rapid” and “very rapid” dissolution speciﬁcations.
MATERIALS AND METHODS
Gastrointestinal Simulation
Gastrointestinal simulation based on the Advanced Com-
partmental Absorption and Transit model (GastroPlus ®
version 5.3.0., SimulationsPlus, Lancaster, CA, USA) was used.
The equations, implemented in GastroPlus®, include the
consideration of six states of drug substance (unreleased,
undissolved, dissolved, degraded, metabolized, and absorbed),
18 compartments (stomach, six compartments for the small
intestine, two colon compartments, and nine enterocyte com-
partments), three states of excreted material (unreleased,
undissolved, and dissolved), and the concentration of drug in
physiologically based organ compartments, when tissue parti-
tion and ﬂow rate parameters are available. The total amount
of absorbed material is summed over the integrated amounts
being absorbed or exsorbed from each absorption or transit
compartment (11).
Drug absorption and disposition was simulated based on
the physicochemical, pharmacokinetic, and virtual drug disso-
lution properties of the selected model drugs. A range of input
parameters related to the drug substance and dosage form
characteristics were experimentally determined and/or taken
from the literature and employed for simulation purposes. A
representative GastroPlus® input dataset is shown for losartan
potassium (Table I). Simulation models used for the other
model drugs investigated, i.e., prednisolon, propranolol, and
ketoprofen, were described and validated previously (7). Part
of the validation process included virtual trial simulations
assuming distributions of physiological variables such as transit
times in the various compartments, pH values in all compart-
ments, and pharmacokinetic parameters as, e.g., systemic
clearance and ﬁrst-pass effect. Random samples of all stochastic
variables were generated for each simulation. The ﬁnal results
were based on virtual trials with 100 volunteers which were
compared to known ranges of concentration versus time
proﬁles.
In Vitro Data
The in vitro dissolution proﬁles used as the input data
were generated on the basis of the case scenario covering the
situation in which comparative dissolution proﬁles (1) could
be described as “rapid” (i.e., more than 85% drug dissolved
in 30 min); but (2) not similar (i.e., similarity factor value, f2,
is 35.37); (3) one of the proﬁles is “very rapid” (i.e., more
than 85% drug dissolved in 15 min); (4) when the 15-min data
points are exempted, the proﬁles are regarded as similar (f2=




Gastrointestinal simulation results for losartan IR tablets
are presented in Fig. 2, together with the actual in vivo C–t
plasma proﬁle observed in the single dose human bioequiva-
lence study (in-house data on file). The predicted pharmacoki-
netic parameters and those observed in vivo were almost
identical as measured by the percent prediction error values
(PE) which were less than 10% for Cmax and AUC values
(PECmax was 5.8%, PEAUC0t was 1.9%, PEAUC0/ was 1.5%
andPEtmax was 10.4%).Good prediction patterns were achieved
for the other model substances as well (data supporting the
validation for these substances were published previously) (7).
Table I. Summary of the Losartan-Potassium Input Parameters






Human jejunal permeability (Peff) 1.15×10
−4 cm/sb
Dose 50 mg
Dose volume 250 ml
Mean precipitation time 900 sc
Drug particle density 1.2 g/mlc
Effective particle radius 25 µmc
Diffusion coefﬁcient 0.75×105 cm2/s
First Pass Extraction 67%a
Unbound percent in plasma (fu) 3%
d
Clearance (CL) 36 L/hd
Volume of distribution (Vc) 1.5 L/kg
Elimination half-life (t1/2) 1.99 h
d
Body weight 69 kg
Simulation time 16 h
aLiterature value taken from (12)
bLiterature value taken from (13)
cDefault GastroPlus values
dLiterature value taken from (14)
Fig. 1. Virtual drug dissolution proﬁles
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Gastrointestinal Simulation—Inﬂuence of Dissolution Rate
on Drug Disposition Prediction
Pharmacokinetic parameters predicted by GST based on
different input dissolution proﬁles (I and II, with or without
15-min data point) are presented in Table II, together with
the actual data observed in the relevant in vivo studies.
According to the results obtained, it is evident that regardless
of the different physicochemical and/or pharmacokinetic
properties of the selected model drugs, predicted drug
behavior in vivo remains almost unaffected by the differences
in the in vitro input kinetics employed.
It is generally accepted that in the case of highly soluble
drugs, drug absorption rate is limited by gastric emptying
time. Although relatively variable, gastric emptying time
under fasting conditions accounts to approximately 60 min
(15). In our simulations, the transit time in the stomach
compartment was set at 0.25 h, representing the lowest
physiologically relevant value. This was considered as the
most discriminative simulation approach since it was expected
that the differences in the early time points of the input data
would have the major impact on drug absorption rate
parameters (Cmax, tmax). However, there were no differences
observed in the predicted proﬁles whether the complete drug
dissolution occurred in 15 min or the percent drug dissolved in
15min was 50%. Virtual dissolution proﬁles representing “rapid
dissolution” scenario (II, Ia, and IIa) resulted in the super-
imposable predicted drug plasma C–t curves when compared to
the “very rapid dissolution” (dissolution proﬁle I). Such data
indicate that the speciﬁcation of “not less than 85% dissolution
in 30 min” should be considered as a rational requirement for
biowaiver justiﬁcation in the case of highly soluble drugs.
Results of the present simulations are in accordance with in
vivo data reported suggesting that differences in the dissolution
proﬁles during the ﬁrst 30 min may not be relevant for rapidly
dissolving formulations of BCS class 1 drugs (8). Such ﬁndings
support the proposal for single-point dissolution requirement
for highly soluble drugs to be reconsidered. The results obtained
also indicate that the 15-min data point is of no critical
importance and that similarity factor (f2) value higher than 50
may be too conservative for dissolution proﬁles comparison and
merits further evaluation.
BCS-based biowaiver justiﬁcation, although becoming
increasingly routine, still face many barriers that limit its
broader application. Lack of international harmonization on
the topic, as well as the uncertainty of acceptance by the
regulatory agency, are quoted as the reasons for the reluctance
to apply for biowaivers (16). Modeling and simulation is
generally, underutilized in assessing bioequivalence in the
pharmaceutical industry due to lack of conﬁdence in the
fundamentals of this approach and lack of experience with
Fig. 2. Predicted (line) and observed (filled circles) mean losartan
plasma C–t proﬁles following administration of a single 50-mg dose
from the IR drug product
Table II. Pharmacokinetic Parameters Predicted Based on the Virtual Dissolution Proﬁles (I, Ia, II, and IIa)
Pharmacokinetic parameter Predicted I Predicted Ia Predicted II Predicted IIa In vivo observed
Losartan (50 mg)
Cmax (μg/mL) 0.111 0.110 0.111 0.111 0.103
AUC0−t (μg h/L) 370.73 370.27 370.73 370.29 363.38
AUC0−∝ (μg h/L) 371.35 370.89 371.35 370.91 365.13
tmax (h) 1.23 1.23 1.23 1.23 1.25
Propranolol (40 mg)
Cmax (μg/mL) 0.027 0.027 0.026 0.027 0.028
AUC0−t (μg h/L) 192.92 192.95 193.11 193.03 227.80
AUC0−∝ (μg h/L) 201.25 201.27 201.37 201.32 –
tmax (h) 2.32 2.32 2.32 2.32 –
Ketoprofen (50 mg)
Cmax (μg/mL) 2.267 2.263 2.242 2.257 3.100–4.500
AUC0−t (μg h/L) 9,755.1 9,755.1 9,755.1 9,755.3 –
AUC0−∝ (μg h/L) 9,771.7 9,771.7 9,771.7 9,771.7 11,524.5
tmax (h) 1.36 1.36 1.44 1.36 1.30
Prednisolon (5 mg)
Cmax (μg/mL) 0.161 0.161 0.160 0.160 0.144
AUC0−t (μg h/L) 644.7 644.7 644.7 644.7 713.6
AUC0−∝ (μg h/L) 651.9 651.9 651.9 651.9 –
tmax (h) 1.72 1.72 1.72 1.72 –
Ia and IIa refer to dissolution proﬁles without 15-min data point
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regulatory acceptance. However, it is the fundamental of a
Quality byDesign approach in drug development and approval.
The results of the present study indicate that Gastrointestinal
Simulation Technology may offer the necessary support in
internal decision making within a pharmaceutical company
when veriﬁcation of certain formulation and/or manufacturing
changes should be performed. A broader use of this method,
however, will need further experience including additional
compounds and their formulations, preferably studied prospec-
tively both in vitro and in vivo.
ACKNOWLEDGEMENT
Part of the study was performed under the project
TR23015, Biopharmaceutical characterization of the selected
BCS classes 2 and 3 model drugs: in vitro and in silico
methods evaluation, funded by the Ministry of Science and
Technological Development, Republic of Serbia.
REFERENCES
1. FDA/CDER. Guidance for industry: Waiver of in vivo bioavail-
ability and bioequivalence studies for immediate-release solid
oral dosage forms based on a Biopharmaceutics Classiﬁcation
System. Washington, DC: FDA; 2000.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical
basis for a biopharmaceutic drug classiﬁcation: the correlation of
in vitro drug product dissolution and in vivo bioavailability.
Pharm Res. 1995;12:413–20.
3. Martinez MN, Amidon GL. a mechanistic approach to under-
standing the effects affecting drug absorption: a review of
fundamentals. J Clin Pharmacol. 2002;42:620–43.
4. FDA/CDER. Guidance for industry: Bioavailability and Bio-
equivalence Studies for Orally Administered Drug Products—
General Considerations. Washington, DC: FDA; 2003.
5. EMEA/CHMP. Note for guidance on the investigation of
bioavailability and bioequivalence. London: EMEA; 2001.
6. Jantratid E, Prekongpans S, Amidon GL, Dressman JB. Feasibil-
ity of biowaiver extension to biopharmaceutics classiﬁcation
system III drug products: Cimetidine. Clin Pharmacokinet.
2006;45: 385–9.
7. Tubic-Grozdanis M, Bolger M, Langguth P. Application of
gastrointestinal simulation for extensions of biowaivers of highly
permeable compounds. AAPS Journal. 2008;10:213–26.
8. Cook J, Addicks W, Wu YH. Application of the biopharmaceut-
ical classiﬁcation system in clinical drug development—an indus-
trial view. AAPS Journal. 2008;10:306–10.
9. ICH. ICH Harmonised Tripartite Guideline—speciﬁcations: test
procedures and acceptance criteria for new drug substances and
new drug products: chemical substances (ICH Q6A). Geneva:
ICH; 1999.
10. EMEA/CHMP. Guideline on the investigation of bioequiva-
lence. London: EMEA; 2008.
11. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of
physiological and biochemical processes on oral drug bioavail-
ability. Adv Drug Deliv Rev. 2001;50:S41–S67.
12. Moffat AC, Osselton MD, Widdop B, Galichet LY, editors.
Clarke’s Analysis of Drugs and Poisons. 3rd ed. London:
Pharmaceutical; 2004.
13. Therapeutic Systems Research Laboratories (TSRL inc.), Bio-
pharmaceutics Classiﬁcation System results for losartan (http://
www.tsrlinc.com/services/bcs/results.cfm; access date December
9th, 2008).
14. Summary of Product Characteristics (SPC), Cozaar Film-Coated
Tablets 100 mg, Merck Sharp and Dohme (revision August
2007). IPHA medicines compendium (www.medicines.ie; access
date December 9th, 2008).
15. Rowland M, Tozer TN. Clinical pharmacokinetics concepts and
applications. Pittsburgh: Williams and Wilkins; 1995.
16. Polli JE, Yu LX, Cook JA. Summary workshop report: biophar-
maceutics classiﬁcation system–implementation challenges and
extension opportunities. J Pharm Sci. 2004;93:1375–81.
384 Kovačević, Parojčić, Tubić-Grozdanis, Langguth
